Kazia Therapeutics Ltd · NASDAQ:KZIA
Kazia Therapeutics — Investor Presentation (October 2020)
35 slides from Kazia Therapeutics's investor presentation, Oct 1, 2020
Slide 1: Kazia Investor Presentation (ASX Release)
ASX RELEASE 1 October 2020 Not for release to US newswire services or distribution in the United States KAZIA INVESTOR PRESENTATION Sydney, 1 October 2020 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide a copy of its
Slide 2: Non-Renounceable Entitlement Offer to Shareholders
NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES Non-Renounceable Entitlement Offer to Shareholders Investor Presentation 1 October 2020 ASX: KZA | NASDAQ : KZIA | Twitter: @KaziaTx
Slide 3: Corporate Overview
Corporate Overview Oncology-focused, mid-clinical-stage, small-molecule Company biotechnology company, headquartered in Sydney, Description Australia Paxalisib – brain-penetrant PI3K / mTOR inhibitor about to enter international phase III for glioblastoma Pipeline Cantrixil – cancer stem cell-target
Slide 4: Chairman's Introduction
Chairman’s Introduction Dear Fellow Shareholders, Our company stands poised to commence the GBM AGILE pivotal study for the registration of our lead program, paxalisib. This is an exciting place to be for any biotech company, and it will launch Kazia on a direct path to commercialisation of this tre
Slide 5: Overview of the Offer
Overview of the Offer A1 for 3 accelerated pro-rata non-renounceable entitlement offer to raise approximately A$25 OFFER STRUCTURE million (Entitlement Offer) via the issue of approximately 31.5 million new ordinary shares (New Shares). All New Shares under the Entitlement Offer will be issued at A$
Slide 6: Use of Funds
Use of Funds Proceeds of the Offer will be used to fund Kazia’s participation in GBM AGILE, the pivotal study for registration of paxalisib in glioblastoma, and for general working capital to the company Timing of Deployment • Kazia anticipates execution of a definitive agreement to operationalise G
Slide 7: Investment Rationale
Investment Rationale • Paxalisib developed by Genentech, the world’s most successful cancer drug company • Well-proven mechanism of action, with unique differentiating factor of brain penetration World-Class Asset in • Strong scientific rationale for development in brain cancer Brain Cancer • Encour
Slide 8: Entitlement Offer Timetable
Entitlement Offer Timetable KZA placed in trading halt on ASX Wednesday 30 September 2020 Institutional Entitlement Offer opens Thursday 1 October 2020 Institutional Entitlement Offer closes Thursday 1 October 2020 Trading halt lifted – shares recommence trading on ASX on an “ex-entitlement” basis F
Slide 9: Program Overview
Program Overview 7
Slide 10: Treatment of brain cancer has improved little in recent decades
Treatment of brain cancer has improved little in recent decades, unlike other cancers Brain Cancer 1990s 2000s 2010s (glioblastoma) Lung 1990s 2000s 2010s Cancer 8
Slide 11: Paxalisib was designed to overcome brain cancer treatment challenges
Paxalisib was designed specifically to overcome challenges associated with brain cancer treatment Challenge Approach Commercially Attractive Blood-Brain Barrier Brain-Penetration • Composition of matter Most cancer therapies do not GDC-0084 is designed to cross the patents through to 2031 penetrate
Slide 12: The PI3K class is well-established, but paxalisib crosses the blood-brain barrier
The PI3K class is well-established, but paxalisib is unique in its ability to cross the blood-brain barrier Zydelig (idelalisib) Aliqopa (copanlisib) Copiktra (duvelisib) Piqray (alpelisib) paxalisib FDA Approved FDA Approved FDA Approved FDA Approved In phase II human trials July 2014 ✓ September 2
Slide 13: Glioblastoma is the most common and aggressive primary brain cancer
Glioblastoma (GBM) is the most common and most aggressive form of primary brain cancer Lung No clear 3-4 months 12-15 cause untreated months Breast or strong risk survival average 14 million factors survival with cancer cases treatment per annum Colon Any age, Five-year Prostate but most survival co
Slide 14: Temozolomide is the only FDA-approved GBM drug; ineffective in ~65%
Temozolomide is only FDA-approved drug for GBM; it is ineffective in ~65% of cases Standard of Care Debulking surgery Radiotherapy + Temozolomide (‘Stupp where possible temozolomide maintenance therapy Regimen’) 6 weeks 4w 6 x 28-day cycles ~35% of patients respond Paxalisib is being developed for t
Slide 15: Ongoing phase II study focuses on newly-diagnosed patients
The ongoing phase II study is designed to focus on newly-diagnosed patients, following radiotherapy Step 1: Dose Optimisation Step 2: Expansion Cohort 9 patients 21 patients • Newly-diagnosed September 2018 – May 2019 June 2019 – February 2020 patients with the unmethylated MGMT promotor (i.e. resis
Slide 16: New phase II data compares favourably to temozolomide
New phase II data compares favourably to historical data for temozolomide (existing standard of care) Progression-Free Survival (PFS) Overall Survival (OS) Part A + Part B (n=30) Part A (n=9) Paxalisib 8.5 months Paxalisib 17.7 months Median PFS Median OS Existing 5.3 months Existing 12.7 months The
Slide 17: A broad-based clinical program across multiple forms of brain cancer
A broad-based clinical program is underway across multiple forms of brain cancer Paxalisib (GDC-0084) Primary Brain Cancer Secondary Brain Cancer (brain cancer that begins in the brain) (brain cancer that spreads from elsewhere in the body) Glioblastoma Glioblastoma DIPG Primary CNS Brain Breast Bra
Slide 18: GBM AGILE is the planned pivotal study for paxalisib
GBM AGILE is the planned pivotal study for paxalisib in glioblastoma What is GBM AGILE? Who is Behind It? • A ‘platform study’, designed by the leading experts in brain cancer to GBM AGILE is sponsored by the Global expedite the approval of new drugs for glioblastoma Coalition for Adaptive Research
Slide 19: GBM AGILE is an adaptive multi-drug registrational study
GBM AGILE is an adaptive multi-drug registrational study, with strong FDA support Drug #1 3 Economies of scale Randomization Drug #2 due to multiple 2 participating drugs allows for large site Comparison against pool, robust study Drug #3, etc… a common control infrastructure, and arm reduces overal
Slide 20: GBM AGILE addresses key challenges faced by small biotechs
GBM AGILE directly addresses the key challenges faced by small biotechs and their investors Challenge Approach Indicative Parameters Limited Funding More Cost-Effective Approach • Primary patient population Many biotech companies cannot AGILE achieves huge efficiencies, and essentially identical to
Slide 21: Recent regulatory achievements position paxalisib for commercialisation
Recent regulatory achievements position paxalisib well as it moves towards commercialisation Glioblastoma DIPG Advantages to Kazia Most common and most Highly aggressive childhood • ‘Data exclusivity’ provides additional aggressive form of brain brain cancer protection against competition cancer bey
Slide 22: Brain cancer is a significant commercial opportunity with limited competition
INDICATIVE Brain cancer represents a significant commercial opportunity for paxalisib, with limited competition Path to Market Expansion Opportunities ‘Blue Sky’ Potential Brain Metastases Glioblastoma (secondary brain cancer) Other Adult Other Cancers with Primary Brain Disordered PI3K 12,500 Cance
Slide 23: Positive newsflow has supported revaluation of Kazia
Positive newsflow has supported revaluation of Kazia as paxalisib moves towards commercialisation Share Price (AU$) KZA 1.20 Market Capitalisation ~AU$ 90 million 1.00 Shares on Issue ~94 million ASX: KZA Listing NASDAQ: KZIA (1:10 ratio) 0.80 Hyecorp 17% (SYD family office) 0.60 Platinum Asset Mgmt
Slide 24: Key Milestones and Anticipated Newsflow
Key Milestones and Anticipated Newsflow Execution of definitive agreement with GCAR for GBM AGILE pivotal study October 2020 Further interim data from Kazia phase II glioblastoma trial November 2020 Initial interim data from phase I DIPG trial at St Jude November 2020 Initial interim data from phase
Slide 25: A strong team with big pharma and biotech experience
A strong team brings international experience in big pharma and early-stage biotech Board Scientific Advisory Board Iain Ross Professor Sir Murray Brennan Chairman Emeritus Chairman of Cancer Surgery at Memorial Sloan Kettering Executive and Board roles in pharma Hospital, New York and small biotech
Slide 26: Appendices
Appendices 24
Slide 27: Important Notice (1/3)
IMPORTANT NOTICE (1/3) This investor presentation (Presentation) has been prepared by Kazia Therapeutics Limited (ACN 063 259 754) (Kazia or Company) in relation to an accelerated non-renounceable entitlement offer of new fully paid ordinary shares in Kazia (New Shares) under section 708AA of the Co
Slide 28: Important Notice (2/3)
IMPORTANT NOTICE (2/3) Readers or recipients of this Presentation should, before making any decisions in relation to their investment or potential investment in Kazia, consider the appropriateness of the information having regard to their own objectives and financial situation and seek their own pro
Slide 29: Important Notice (3/3)
IMPORTANT NOTICE (3/3) Financial information All references to dollars, cents or $ in this Presentation are to Australian currency, unless otherwise stated. Unless otherwise noted, all references to financial information are presented as at the full financial year ended 30 June 2020. Past performanc
Slide 30: Risks of the Investment
RISKS OF THE INVESTMENT COMPANY RISKS Not all drugs at this stage of development reach market. Pivotal clinical studies can demonstrate an unexpected lack of efficacy, or a previously unknown safety concern. Across Technical Success is Uncertain all drugs in development, the probability of a drug in
Slide 31: Risks of the Investment
RISKS OF THE INVESTMENT COMPANY RISKS The company depends on being able to attract and retain personnel with specialist expertise, Kazia is Dependent on Key and to ensure continuity of key management. The loss of one or more key members of the Personnel management team could material affect Kazia’s
Slide 32: Risks of the Investment
RISKS OF THE INVESTMENT OFFER RISKS The rights entitlement structure offers eligible existing shareholders the ability to apply for Demand May Exceed new shares pro rata, and any such applications will be met. The ability of the company to Availability of Stock meet applications by new shareholders
Slide 33: Risks of the Investment
RISKS OF THE INVESTMENT MARKET RISKS There are risks associated with investment in any company listed on the ASX, which include Investment in Public Equities both the financial and operational performance of the company and external factors outside Carries Inherent Risk the company’s control, such a
Slide 34: International Offer Restrictions
INTERNATIONAL OFFER RESTRICTIONS This document does not constitute an offer of new ordinary shares (New Shares) of the Company in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the New Shares may not be offered or sold, in any c
Slide 35: www.kaziatherapeutics.com
www.kaziatherapeutics.com
Kazia Therapeutics — Investor Presentation (October 2020) on 6ix